Magic mushroom compound could ease chronic PTSD in new trial

NCT ID NCT06386003

Recruiting now Symptom relief Sponsor: Unity Health Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with intensive therapy can help people with chronic posttraumatic stress disorder (PTSD). Fifteen adults with moderate to severe PTSD will receive the treatment over a week. The goal is to see if the approach is safe, tolerable, and reduces PTSD symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new treatment option for people with chronic PTSD who haven't responded to standard therapies.
What could go wrong: This is a very small, early-phase trial with only 15 people, so results may not apply to everyone. It's also open-label, meaning both participants and researchers know the treatment, which can bias results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PTSD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC PTSD POST-TRAUMATIC STRESS DISORDER PTSD

Contacts and locations

Locations

St. Michael's Hospital, Unity Health Toronto
RECRUITING

Toronto, Ontario, M5S 1A1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.